<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>DONNATAL Â - phenobarbital, hyoscyamine sulfate, atropine sulfate and scopolamine hydrobromideÂ tabletÂ </strong><br>AvKARE, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Donnatal Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-1"></a><p></p>
<h1>Patient Insert</h1>
<p class="First">DONNATALÂ® TABLETS</p>
<p>Rx Only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Each DonnatalÂ® Tablet contains:<br><br>Phenobarbital, USP .....................................................16.2 mg<br>Hyoscyamine Sulfate, USP .............................................0.1037 mg<br>Atropine Sulfate, USP.....................................................0.0194 mg<br>Scopolamine Hydrobromide, USP .................................0.0065 mg</p>
</div>
<div class="Section" data-sectionCode="51727-6">
<a name="section-3"></a><p></p>
<h1>INACTIVE INGREDIENTS:</h1>
<p class="First">Anhydrous Lactose, Calcium Stearate, Colloidal Silicon Dioxide, Corn Starch, and Microcrystalline Cellulose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">This drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital toÂ  provide peripheral anticholinergic/antispasmodic action and mild sedation.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<table border="1" cellpadding="4" cellspacing="0" width="100%"><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the following indications as â€œpossiblyâ€? effective: For use as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (<span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable colon</span>, <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">spastic colon</span>, <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">mucous colitis</span>) and acute <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>.May also be useful as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>.Â  IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">DUODENAL ULCER</span>, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS.</td></tr></tbody></table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>, <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span> (for example, <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span> due to <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>; severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> especially if complicated by toxic mega-colon; <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>; <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatal hernia</span> associated with <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">reflux esophagitis</span>.<br><br>DonnatalÂ® is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients.Â  Phenobarbital is contraindicated in <span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">acute intermittent porphyria</span> and in those patients in whom phenobarbital produces <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and/or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">In the presence of a high environmental temperature, <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> can occur with belladonna alkaloids (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and heatstroke due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>). <br><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may be an early symptom of incomplete <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful.<br><br>DonnatalÂ® may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. The patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.<br><br>Phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. When the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased. <br>Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> upon drugs.<br><br>Since barbiturates are metabolized in the liver, they should be used with caution and initial doses should be small in patients with hepatic dysfunction.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS:</h1>
<p class="First">Use with caution in patients with: <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span>, hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.<br><br>Belladonna alkaloids may produce a delay in gastric emptying (antral stasis) which would complicate the management of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>.<br><br>Do not rely on the use of the drug in the presence of complication of <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>.<br><br>Theoretically, with overdosage, a curare-like action may occur.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-9"></a><p></p>
<h1>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY:</h1>
<p class="First">Long-term studies in animals have not been performed to evaluate carcinogenic potential.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-10"></a><p></p>
<h1>PREGNANCY:</h1>
<p class="First">PREGNANCY CATEGORY C<br>Â Animal reproduction studies have not been conducted with DonnatalÂ®. It is not known whether DonnatalÂ® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.Â  DonnatalÂ® should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-11"></a><p></p>
<h1>NURSING MOTHERS.</h1>
<p class="First">It is not known whether this drug is excreted in human milk.Â  Because many drugs are excreted in human milk, caution should be exercised when DonnatalÂ® is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-12"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">Adverse reactions may include <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">xerostomia</span>; <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span> and retention; <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>; <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>; <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>; increased ocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>; <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span> sense; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>; <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>; suppression of lactation; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">bloated feeling</span>; <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>; severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> or drug idiosyncrasies, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and other dermal manifestations; and decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. Acquired <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to barbituates consists chiefly in <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> that occur especially in persons who tend to have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, angiodema and similar conditions. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> in this category include localized <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, particularly of the eyelids, cheeks, or lips, and erythematous <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>. Rarely, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> (e.g. <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) may be caused by phenobarbital and can prove fatal. The <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruption</span> may be associated with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and marked degenerative changes in the liver and other parenchymatous organs. In a few cases, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> has been associated with the chronic use of phenobarbital. Elderly patients may react with symptoms of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and other untoward manifestations to even small doses of the drug. Phenobarbital may produce <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> in some patients, rather than a sedative effect.Â  In patients habituated to barbiturates, abrupt withdrawal may produce <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.<br><br>To report SUSPECTED ADVERSE REACTIONS, contact AvKARE, Inc. at 1-855-361-3993 or the<br>FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.<br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-13"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">The dosage of DonnatalÂ® should be adjusted to the needs of the dividual patient to assure symptomatic control with a minimum of adverse effects. <br><br>DonnatalÂ® Tablets. Adults: One or two DonnatalÂ® tablets three or four times a day according to condition and severity of symptoms.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-14"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">The signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, hot and <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, dryness of the mouth, difficulty in swallowing, and CNS stimulation.Â  Treatment should consist of gastric lavage, emetics, and activated charcoal.Â  If indicated, parenteral cholinergic agents such as physostigmine or bethanechol chloride, should be used.</p>
<p><span class="Bold">HOW SUPPLIED: </span>DonnatalÂ® Tablets are supplied as: White, D-shaped tablets debossed â€œDâ€? on one side and â€œDonnatalâ€? on the other side.<br><br>Bottles of 100 tablets - NDC 42291-245-01<br><br><span class="Bold">AVOID FREEZING<br><br></span>Store at 20-25Â°C (68-77Â°F) [See USP Controlled Room Temperature].<br><br>Protect from light and moisture.<br></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Use safety closures when dispensing this product unless otherwise directed by a physician or requested by purchaser.<br><br>Also available: DonnatalÂ® Elixir, grape flavored liquid, in 4 fl oz (118mL) and 1 pint (473mL) bottles<br><br>Manufactured for:<br><span class="Bold">AvKARE, Inc</span>. <br>Pulaski, TNÂ  38478<br><br>Mfg. Rev. 12/13Â Â Â  AV 12/13 ( P)<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_b05cee3c-7767-e160-dacc-e2df9180a4da"></a><a name="section-15"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">AvKARE<br><br>NDC </span>42291-245-01<br><br><span class="Bold">Donnatal<br></span><br>Each tablet contains:<br>Phenobarbital, USP......................16.2 mg<br>Hyoscyamine Sulfate, USP......0.1037 mg<br>Atropine Sulfate, USP..............0.0194 mg<br>Scoplamine<br>Hydrobromide, USP.................0.0065 mg<br><br><span class="Bold">100 TabletsÂ Â Â Â Â Â  Rx Only</span><br></p>
<p><span class="Bold">USUAL ADULT DOSAGE:<br></span>See accompanying product literature for complete information.<br><br><span class="Bold">Store </span>at 20<span class="Sup">o</span>-25<span class="Sup">o</span>C (68<span class="Sup">o</span>-77<span class="Sup">o</span>F) [see USP Controlled Room Temperature].<br><br><span class="Bold">Dispense </span>in a tight, light-resistant container as defined in the USP using a child-resistant enclosure.<br></p>
<p><span class="Bold">Keep out of the reach of children.</span></p>
<p>Manufactured for:<br><span class="Bold">AvKARE, Inc.</span><br>Pulaski, TN 38478<br><br>Mfg. Rev. 12/12Â Â Â Â Â Â  AV 12/13 (P)<br></p>
<p><span class="Bold">N</span>3Â Â  42291-245-01Â Â  3  </p>
<div class="Figure"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=935b19ba-1e17-99c3-6c22-1e21fd8263df&amp;name=Screen%20Shot%202014-01-06%20at%208.56.29%20AM.jpg"></div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-16"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DONNATAL Â 		
					</strong><br><span class="contentTableReg">phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42291-245(NDC:59212-425)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Phenobarbital</strong> (Phenobarbital) </td>
<td class="formItem">Phenobarbital</td>
<td class="formItem">16.2Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYOSCYAMINE SULFATE</strong> (HYOSCYAMINE) </td>
<td class="formItem">HYOSCYAMINE SULFATE</td>
<td class="formItem">0.1037Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ATROPINE SULFATE</strong> (ATROPINE) </td>
<td class="formItem">ATROPINE SULFATE</td>
<td class="formItem">0.0194Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SCOPOLAMINE HYDROBROMIDE</strong> (SCOPOLAMINE) </td>
<td class="formItem">SCOPOLAMINE HYDROBROMIDE</td>
<td class="formItem">0.0065Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">SEMI-CIRCLE (D-shaped tablet) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">D;Donnatal</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42291-245-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">01/06/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>AvKARE, Inc.
							(796560394)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ccec158d-edb4-5da0-d891-376de835259a</div>
<div>Set id: 935b19ba-1e17-99c3-6c22-1e21fd8263df</div>
<div>Version: 3</div>
<div>Effective Time: 20150921</div>
</div>
</div>Â <div class="DistributorName">AvKARE, Inc.</div></p>
</body></html>
